AR076621A1 - Composiciones para el suministro de antagonistas muscarinicos de accion prolongada y agonista del receptor adrenergico b2 de accion prolongada. metodo de tratamiento. sistemas asociados. inhalador dosificador - Google Patents

Composiciones para el suministro de antagonistas muscarinicos de accion prolongada y agonista del receptor adrenergico b2 de accion prolongada. metodo de tratamiento. sistemas asociados. inhalador dosificador

Info

Publication number
AR076621A1
AR076621A1 ARP100101885A ARP100101885A AR076621A1 AR 076621 A1 AR076621 A1 AR 076621A1 AR P100101885 A ARP100101885 A AR P100101885A AR P100101885 A ARP100101885 A AR P100101885A AR 076621 A1 AR076621 A1 AR 076621A1
Authority
AR
Argentina
Prior art keywords
active agent
particles
pharmaceutically acceptable
cosuspension
metered dose
Prior art date
Application number
ARP100101885A
Other languages
English (en)
Spanish (es)
Inventor
Michael Steven Hartman
Adrian Edward Smith
Vidya B Joshi
Reinhard Vehring
Sarvajna Kumar Dwivedi
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42269864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076621(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of AR076621A1 publication Critical patent/AR076621A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1025—Respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
ARP100101885A 2009-05-29 2010-05-28 Composiciones para el suministro de antagonistas muscarinicos de accion prolongada y agonista del receptor adrenergico b2 de accion prolongada. metodo de tratamiento. sistemas asociados. inhalador dosificador AR076621A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18256509P 2009-05-29 2009-05-29
US25817209P 2009-11-04 2009-11-04
US30936510P 2010-03-01 2010-03-01
US34553610P 2010-05-17 2010-05-17

Publications (1)

Publication Number Publication Date
AR076621A1 true AR076621A1 (es) 2011-06-22

Family

ID=42269864

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP100101885A AR076621A1 (es) 2009-05-29 2010-05-28 Composiciones para el suministro de antagonistas muscarinicos de accion prolongada y agonista del receptor adrenergico b2 de accion prolongada. metodo de tratamiento. sistemas asociados. inhalador dosificador
ARP100101884A AR076807A1 (es) 2009-05-29 2010-05-28 Composiciones metodos y sistemas para el suministro de dos o mas agentes activos mediante las vias respiratorias. metodo de preparacion composicion
ARP100101882A AR076806A1 (es) 2009-05-29 2010-05-28 Composiciones para el suministro de agentes activos mediante las vias res-piratorias, y metodos y sistemas asociados, cosuspension, inhalador dosifi-cador

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP100101884A AR076807A1 (es) 2009-05-29 2010-05-28 Composiciones metodos y sistemas para el suministro de dos o mas agentes activos mediante las vias respiratorias. metodo de preparacion composicion
ARP100101882A AR076806A1 (es) 2009-05-29 2010-05-28 Composiciones para el suministro de agentes activos mediante las vias res-piratorias, y metodos y sistemas asociados, cosuspension, inhalador dosifi-cador

Country Status (31)

Country Link
US (12) US8808713B2 (enExample)
EP (6) EP2435024B1 (enExample)
JP (10) JP5823383B2 (enExample)
KR (7) KR20190049943A (enExample)
CN (6) CN107412212B (enExample)
AR (3) AR076621A1 (enExample)
AU (3) AU2010253770B9 (enExample)
BR (3) BRPI1011220B1 (enExample)
CA (3) CA2763939A1 (enExample)
CY (8) CY1118040T1 (enExample)
DK (6) DK2435023T3 (enExample)
ES (6) ES2593429T3 (enExample)
FR (1) FR19C1040I2 (enExample)
HR (6) HRP20161098T1 (enExample)
HU (8) HUE047834T2 (enExample)
IL (3) IL216466B (enExample)
LT (8) LT3106149T (enExample)
LU (2) LUC00124I2 (enExample)
ME (1) ME03631B (enExample)
MX (5) MX393243B (enExample)
NL (1) NL300995I2 (enExample)
NO (2) NO2019026I1 (enExample)
PH (1) PH12017500778A1 (enExample)
PL (6) PL3111927T3 (enExample)
PT (6) PT2435024T (enExample)
RU (5) RU2751771C2 (enExample)
SI (6) SI3106149T1 (enExample)
SM (6) SMT202000108T1 (enExample)
TW (9) TWI695723B (enExample)
WO (3) WO2010138862A2 (enExample)
ZA (4) ZA201108275B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
US10002325B2 (en) 2005-03-30 2018-06-19 Primal Fusion Inc. Knowledge representation systems and methods incorporating inference rules
KR101486397B1 (ko) 2005-09-14 2015-01-28 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
US10675417B2 (en) * 2006-03-07 2020-06-09 Leibovici, Llc Method and apparatus for applying an anesthetic and bactericide
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
MX2010014240A (es) 2008-06-20 2011-03-25 Mankind Corp Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SI3106149T1 (sl) * 2009-05-29 2020-07-31 Pearl Therapeutics, Inc. Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi
BR112012033060A2 (pt) * 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
US10474647B2 (en) 2010-06-22 2019-11-12 Primal Fusion Inc. Methods and devices for customizing knowledge representation systems
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
MX2013013440A (es) * 2011-05-17 2014-06-05 Pearl Therapeutics Inc Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos.
CN105106200A (zh) * 2011-05-17 2015-12-02 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
BR112014025518B1 (pt) * 2012-04-13 2022-05-24 Glaxosmithkline Intellectual Property Development Limited Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
CN102872027B (zh) * 2012-09-18 2014-03-12 刘晓忠 一种治疗肺部疾病的药物颗粒的制备和吸入式复方气雾剂的制备
DK2948148T3 (da) * 2013-01-28 2020-10-26 Incozen Therapeutics Pvt Ltd Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid
AU2014210942A1 (en) * 2013-01-31 2015-08-20 Prosonix Limited Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
GB201301721D0 (en) * 2013-01-31 2013-03-20 Prosonix Ltd Pharmaceutical Preparations
HRP20201103T1 (hr) * 2013-03-04 2021-02-05 Besins Healthcare Luxembourg Sarl Suhi farmaceutski pripravci koji sadrže nanočestice aktivnog sredstva vezane za čestice nosača
CA2898700C (en) * 2013-03-14 2022-07-19 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
HK1219059A1 (zh) * 2013-03-15 2017-03-24 珍珠治疗公司 用於微粒晶体材料的状态调节的方法和系统
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
WO2014190204A1 (en) * 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
CN114848614A (zh) 2013-07-18 2022-08-05 曼金德公司 热稳定性干粉药物组合物和方法
CN105636630B (zh) * 2013-10-07 2020-05-19 梯瓦优质制药产品研发股份有限公司 干粉吸入器
PL2897589T3 (pl) * 2013-11-22 2018-06-29 Teva Branded Pharmaceutical Products R & D, Inc. Lek do inhalacji
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
CN104188941B (zh) * 2014-09-02 2016-11-16 重庆和平制药有限公司 一种制备盐酸克仑特罗吸入粉雾剂的方法
KR20170057451A (ko) * 2014-10-01 2017-05-24 에이엘에스 마운틴 엘엘씨 비이온성 계면 활성제와 함께 아스피린, 메트포르민 및 세로토닌을 포함하는 약학 조성물
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2016170518A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
WO2017108917A1 (en) 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
WO2017157265A1 (zh) * 2016-03-15 2017-09-21 广东东阳光药业有限公司 喷雾剂、喷雾装置以及喷雾组件
WO2017201003A1 (en) * 2016-05-17 2017-11-23 Mayo Foundation For Medical Education And Research Materials and methods for treating chronic cough
EP3478265B1 (en) 2016-06-30 2025-01-01 Philip Morris Products S.A. Nicotine particles
US10888546B2 (en) * 2016-09-19 2021-01-12 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
JP6906947B2 (ja) * 2016-12-22 2021-07-21 キヤノン株式会社 画像処理装置、撮像装置、画像処理方法およびコンピュータのプログラム
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
CN107243080B (zh) * 2017-06-21 2021-11-12 上海上药信谊药厂有限公司 一种吸入式气雾剂、其原料组合物及制备方法
US11833292B2 (en) * 2017-10-09 2023-12-05 Pearl Therapeutics, Inc. Drug delivery systems and related methods
JP7372727B2 (ja) 2017-11-20 2023-11-01 三菱重工業株式会社 系統運用者側コンピュータ、発電事業者側コンピュータ、電力システム、制御方法及びプログラム
WO2020070620A2 (en) * 2018-10-01 2020-04-09 3M Innovative Properties Company Formulation and aerosol canisters, inhalers, and the like containing the formulation
US20210386665A1 (en) * 2018-10-02 2021-12-16 Meijo University Educational Foundation Inhalation powder medicine, evaluation method thereof, and use thereof
CN109632555B (zh) * 2018-12-28 2021-07-27 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法
WO2020229966A1 (en) * 2019-05-10 2020-11-19 Glenmark Pharmaceutical Limited Stable aerosol composition for inhalation comprising glycopyrronium
CN112137957B (zh) 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
WO2020263994A1 (en) * 2019-06-27 2020-12-30 Cai Gu Huang Inhalable formulation of a solution containing formoterol fumarate and aclidinium bromide
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
WO2021165348A1 (en) * 2020-02-20 2021-08-26 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
EP3962455B1 (en) 2020-05-18 2022-08-31 Orexo AB New pharmaceutical composition for drug delivery
US20220000767A1 (en) * 2020-07-06 2022-01-06 Sensory Cloud, Inc. Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi
WO2022016068A1 (en) * 2020-07-16 2022-01-20 Tbd Pharma Llc Dexamethasone solution for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections
WO2022073009A1 (en) 2020-09-29 2022-04-07 iPharma Labs, Inc. Liquid formulations of indacaterol
CN116710104A (zh) * 2021-01-08 2023-09-05 江苏恒瑞医药股份有限公司 可通过定量吸入器递送的药物组合物
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
ES2981514T3 (es) 2021-07-09 2024-10-09 Astrazeneca Pharmaceuticals Lp Composiciones, métodos y sistemas para el suministro de fármacos en aerosol
WO2023094826A1 (en) 2021-11-25 2023-06-01 Orexo Ab Pharmaceutical composition comprising adrenaline
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
CN116785239A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 喷雾冷冻干燥制备微球的方法
JP2025518628A (ja) * 2022-04-28 2025-06-18 アストラゼネカ・アクチエボラーグ 喘息の治療のための医薬組成物及び方法
WO2024206662A1 (en) * 2023-03-30 2024-10-03 Aerorx Therapeutics Llc Liquid formulations of indacaterol and glycopyrronium
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用
US20250268914A1 (en) * 2024-02-26 2025-08-28 Honeywell International Inc. Fluticasone delivery compositions, devices and methods
CN118787617A (zh) * 2024-09-14 2024-10-18 苏州易合医药有限公司 一种吸入粉剂及其制备方法

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (enExample) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
CA1201114A (en) * 1980-02-15 1986-02-25 Gordon H. Phillipps Androstane carbothioates
ATE8790T1 (de) * 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
EP0416950B1 (en) 1989-09-08 1993-08-11 Glaxo Group Limited Medicaments
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
CA2091360C (en) 1990-09-10 1997-04-08 Pui-Ho Yuen Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
DE4108393A1 (de) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
US5635563A (en) 1991-04-01 1997-06-03 Tomoegawa Paper Co., Ltd. Polyaniline derivatives and their production process
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
SK282826B6 (sk) 1991-12-18 2002-12-03 Aktiebolaget Astra Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5849263A (en) 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
PT731688E (pt) 1993-12-02 2003-07-31 Abbott Lab Formulacoes de farmacos em aerossol para utilizacao com propulsores sem cfc
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
DE69502179D1 (de) 1994-02-09 1998-05-28 Kinerton Ltd Verfahren zur trocknung eines materials aus einer lösung
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
CN1088580C (zh) * 1994-12-22 2002-08-07 阿斯特拉公司 气溶胶药物制剂
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
KR19980703876A (ko) 1995-04-14 1998-12-05 스티븐 엘. 허스트 분산성이 개선된 분말화된 약학적 조성물
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
DE19614421C2 (de) 1996-04-12 1999-12-16 Biovision Gmbh Verfahren zur Herstellung eines biodegradierbaren Knochenersatz- und Implantatwerkstoffes und biodegradierbarer Knochenersatz- und Implantatwerkstoff
GB9610821D0 (en) 1996-05-23 1996-07-31 Glaxo Wellcome Inc Metering apparatus
US6054488A (en) 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6068832A (en) 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
DK0937041T3 (da) * 1996-11-11 2003-08-11 Christian R Noe Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
CZ295460B6 (cs) 1997-03-20 2005-08-17 Schering Corporation Způsob výroby aglomerátů a jednotková dávka farmakologicky aktivní látky je obsahující
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US6010935A (en) * 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
ATE239447T1 (de) * 1997-09-29 2003-05-15 Inhale Therapeutic Syst In verneblern verwendbare, stabilisierte zubereitungen
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
BR9908566A (pt) 1998-03-05 2000-11-21 Senju Pharma Co Composição farmacêutica para profilaxia e terapia de doenças associadas a citopatia do tecido do fundo ocular
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6260549B1 (en) * 1998-06-18 2001-07-17 Clavius Devices, Inc. Breath-activated metered-dose inhaler
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6585958B1 (en) 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
AU749697B2 (en) 1998-08-04 2002-07-04 Jagotec Ag Medicinal aerosol formulations
CA2347856C (en) * 1998-11-13 2009-02-17 Jagotec Ag Dry powder for inhalation
GB9912639D0 (en) 1999-05-28 1999-07-28 Britannia Pharmaceuticals Ltd Improvements in and relating to treatment of respiratory conditions
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
EP2258183A1 (en) 1998-12-22 2010-12-08 The University of North Carolina at Chapel Hill Compounds and uses for the treatment of airway diseases and for the delivery of airway drugs
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
PL196951B1 (pl) 1999-03-05 2008-02-29 Chiesi Farma Spa Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika
SE9900833D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
ES2193069T3 (es) 1999-04-14 2003-11-01 Glaxo Group Ltd Formulacion farmaceutica en aerosol.
US20100197719A1 (en) 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
HK1044130B (en) 1999-06-30 2008-03-14 Nektar Therapeutics Spray drying process and system for preparing dry powders
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
PT102343B (pt) * 1999-08-02 2003-11-28 Hovione Farmaciencia Sa Processo para a preparacao de furoato mometasona
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
CN1188111C (zh) 1999-10-29 2005-02-09 耐科塔医药公司 分散性得到改进的干粉组合物
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
AU2001252350A1 (en) 2000-04-13 2001-10-30 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
WO2001085136A2 (en) * 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
AU2000265583A1 (en) 2000-08-15 2002-02-25 Carsten Berg Quaternary ammonium salts of 1,2-benzisothiazolin-3-one. preparation and use as biocides
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
JP4380988B2 (ja) * 2000-11-30 2009-12-09 ヴェクトゥラ リミテッド 医薬組成物に用いられる粒子の製造方法
ES2587135T3 (es) 2000-11-30 2016-10-20 Vectura Limited Procedimiento de fabricación de partículas para su uso en una composición farmacéutica
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
AU2002230993B2 (en) 2000-12-29 2006-02-02 Alkermes, Inc. Particles for inhalation having sustained release properties
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
IL157580A0 (en) * 2001-03-20 2004-03-28 Glaxo Group Ltd Inhalation drug combination
US20050074742A1 (en) * 2001-03-30 2005-04-07 Alain Domard Cartilaginous neo-tissue capable of being grafted
PT1372608E (pt) * 2001-03-30 2008-01-04 Jagotec Ag Formulações de aerossol médicas
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
DE10202940A1 (de) * 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
DE10214264A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen eines Anhydrats
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
AU2003276837B2 (en) * 2002-06-12 2006-07-20 Epigenesis Pharmaceuticals, Llc. Combination of anti-muscarinic agents and non-glucocorticoid steroids
US7244742B2 (en) 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
DE10237739A1 (de) 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
CA2495689A1 (en) 2002-08-23 2004-03-04 Schering Corporation Pharmaceutical compositions
CA2500065A1 (en) 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
ES2331793T3 (es) 2002-10-15 2010-01-15 Cryovac, Inc. Procedimiento para estimular, almacenar y distribuir un captador de oxigeno, y un captador de oxigeno almacenado.
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
DE10323966A1 (de) 2003-05-27 2004-12-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
CA2523475C (en) 2003-05-28 2013-02-05 Nektar Therapeutics Pharmaceutical formulation comprising a water-insoluble active agent
WO2004110450A1 (en) * 2003-06-16 2004-12-23 Altana Pharma Ag Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases
SE527190C2 (sv) 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
EP1651221B1 (en) 2003-07-28 2009-01-14 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising betamimetics and an anticholinergic agent
BRPI0413129A (pt) 2003-07-29 2006-10-03 Boehringer Ingelheim Int medicamentos para inalação compreendendo betamiméticos e anticolinérgico
NZ545443A (en) 2003-07-29 2010-04-30 Boehringer Ingelheim Int Combination of an aclidinium salt known as 3-(2-hydroxy-2,2-dithiophen-2-yl-acetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane and a steroid and its use to treat respiratory disorders by inhalation
ATE526967T1 (de) 2003-07-31 2011-10-15 Boehringer Ingelheim Int Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
EP1925293A3 (en) 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
JP4851937B2 (ja) * 2003-11-21 2012-01-11 セラヴァンス， インコーポレーテッド β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
CA2552641A1 (en) 2003-12-31 2005-07-21 Cydex, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
EP1718336B1 (en) 2004-02-06 2008-06-25 MEDA Pharma GmbH & Co. KG Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
JP4819699B2 (ja) 2004-02-06 2011-11-24 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト 喘息及びｃｏｐｄの長期間の治療のための抗コリン作用薬及びグルココルチコイドの組合せ剤
WO2005077339A1 (en) * 2004-02-10 2005-08-25 E.I. Dupont De Nemours And Company Process for preparing stable sol of pharmaceutical ingredients and hydrofluorocarbon comprising milling the said sol, then transfert it into a canister
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006002178A1 (en) * 2004-06-18 2006-01-05 Novartis Vaccines And Diagnostics Inc. Methods of treatment of endobronchial infections
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
US20060140873A1 (en) 2004-12-27 2006-06-29 Chang Heng W Aerosol pharmaceutical compositions
EP1861361A1 (en) 2005-03-24 2007-12-05 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
MX2007012084A (es) 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
CA2607391A1 (en) 2005-04-23 2006-11-02 Boehringer Ingelheim International Gmbh Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
JP2008542332A (ja) 2005-05-31 2008-11-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患治療用新規医薬組成物
WO2006134022A1 (en) 2005-06-17 2006-12-21 Boehringer Ingelheim International Gmbh Mrp iv inhibitors for the treatment of respiratory diseases
AU2006272438B2 (en) 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
US20100183725A1 (en) 2005-07-15 2010-07-22 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
CN100560598C (zh) 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
AT502396B1 (de) 2005-09-01 2007-03-15 Montanuniv Leoben Verfahren zum abtrennen von verunreinigungen aus einsatzstoffen
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
DE602006008665D1 (de) 2005-12-21 2009-10-01 Meda Pharma Gmbh & Co Kg Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
AR059358A1 (es) * 2006-02-09 2008-03-26 Schering Corp Formulaciones farmaceuticas
EP2029126A1 (en) 2006-05-24 2009-03-04 Boehringer Ingelheim International GmbH Novel medicament combinations for the treatment of respiratory diseases
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0614621D0 (en) 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP2124915A2 (en) * 2007-02-19 2009-12-02 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
EP1964564A1 (en) * 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
EP2036572A1 (en) 2007-09-04 2009-03-18 Novo Nordisk A/S Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle
CN101317821B (zh) * 2007-11-15 2012-01-04 陈晓东 适用于肺部给药的超细干粉颗粒及其制备方法
JP2011506399A (ja) * 2007-12-13 2011-03-03 ノバルティス アーゲー 有機化合物
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
FR2940162B1 (fr) 2008-12-22 2011-02-25 Boehm & Cie Ets Outil de frappe multi-usages a mecanisme absorbant l'energie transmise au moyen de prehension
WO2010097188A1 (en) 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
SI3106149T1 (sl) 2009-05-29 2020-07-31 Pearl Therapeutics, Inc. Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
BR112012024059B1 (pt) 2010-04-01 2021-06-01 Chiesi Farmaceutici S.P.A. Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco
EP2627317A4 (en) 2010-10-15 2014-08-20 Glaxo Group Ltd MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE
RU2013142268A (ru) 2011-02-17 2015-03-27 Сипла Лимитед Фармацевтическая композиция
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
MX2013013440A (es) 2011-05-17 2014-06-05 Pearl Therapeutics Inc Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos.
WO2014190204A1 (en) 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents

Also Published As

Publication number Publication date
SI2435024T1 (sl) 2016-10-28
SI3106149T1 (sl) 2020-07-31
HUE047803T2 (hu) 2020-05-28
JP2012528200A (ja) 2012-11-12
WO2010138884A3 (en) 2011-04-21
MX2011012783A (es) 2012-06-28
PH12017500778A1 (en) 2018-01-22
JP6492124B2 (ja) 2019-03-27
US20150017247A1 (en) 2015-01-15
HRP20161101T1 (hr) 2016-11-04
CY2021012I2 (el) 2021-10-15
PT2435024T (pt) 2016-10-13
AU2010253950B2 (en) 2014-12-04
KR20180130602A (ko) 2018-12-07
MX337126B (es) 2016-02-12
US20110132356A1 (en) 2011-06-09
DK2435024T3 (en) 2016-10-24
ES2589135T3 (es) 2016-11-10
IL216467A0 (en) 2012-01-31
SI3111927T1 (sl) 2020-08-31
TWI539979B (zh) 2016-07-01
JP2012528199A (ja) 2012-11-12
DK2435025T3 (en) 2016-10-24
JP5873013B2 (ja) 2016-03-01
JP2016041713A (ja) 2016-03-31
CA2763941A1 (en) 2010-12-02
EP2435025A2 (en) 2012-04-04
CN107412212B (zh) 2021-01-22
IL216467B (en) 2018-12-31
LT2435024T (lt) 2016-09-26
EP3106149A1 (en) 2016-12-21
LTC2435024I2 (enExample) 2022-06-27
MX377778B (es) 2025-03-11
SMT201600326B (it) 2016-11-10
WO2010138868A2 (en) 2010-12-02
SI3111926T1 (sl) 2020-07-31
HRP20161102T1 (hr) 2016-11-04
HRP20200260T1 (hr) 2020-05-29
CY1122732T1 (el) 2021-03-12
DK3111926T3 (da) 2020-03-02
US20190307676A1 (en) 2019-10-10
CA2763939A1 (en) 2010-12-02
FR19C1040I2 (fr) 2020-07-31
HK1218867A1 (zh) 2017-03-17
NL300995I1 (enExample) 2019-06-24
TW202114642A (zh) 2021-04-16
ZA201208102B (en) 2013-09-25
JP2018048150A (ja) 2018-03-29
CY2021012I1 (el) 2021-10-15
SMT201600327B (it) 2016-11-10
DK3111927T3 (da) 2020-03-09
RU2586297C2 (ru) 2016-06-10
TW201109050A (en) 2011-03-16
EP3106149B1 (en) 2019-11-20
AU2010253770A1 (en) 2011-11-24
HK1169307A1 (zh) 2013-01-25
SMT201600329B (it) 2016-11-10
TWI632926B (zh) 2018-08-21
KR20120034631A (ko) 2012-04-12
LTC2435025I2 (lt) 2021-02-10
RU2020102859A (ru) 2021-07-26
CN102753152A (zh) 2012-10-24
RU2016107464A (ru) 2018-11-22
AU2010253950A1 (en) 2011-12-08
EP2435023A2 (en) 2012-04-04
CN107669664A (zh) 2018-02-09
AU2010253770B9 (en) 2015-02-12
US20190038548A1 (en) 2019-02-07
TWI546094B (zh) 2016-08-21
RU2713404C2 (ru) 2020-02-05
ES2772253T3 (es) 2020-07-07
TWI695723B (zh) 2020-06-11
JP6189356B2 (ja) 2017-08-30
CY2019031I1 (el) 2019-11-27
FR19C1040I1 (enExample) 2020-07-31
ZA201108275B (en) 2023-04-26
PT3106149T (pt) 2020-02-19
AU2010253950C1 (en) 2015-09-17
HK1244669A1 (zh) 2018-08-17
CA2763936A1 (en) 2010-12-02
BRPI1011220A2 (pt) 2016-03-15
LT2435023T (lt) 2016-09-26
PT2435023T (pt) 2016-10-14
RU2015151358A (ru) 2019-01-16
CY1122749T1 (el) 2021-03-12
AR076806A1 (es) 2011-07-06
MX2011012684A (es) 2012-05-23
DK3106149T3 (da) 2020-02-24
PL3111927T3 (pl) 2020-06-29
TWI707700B (zh) 2020-10-21
PL2435023T3 (pl) 2017-06-30
EP3111926A1 (en) 2017-01-04
JP5823383B2 (ja) 2015-11-25
JP6348645B2 (ja) 2018-06-27
SI2435025T1 (sl) 2016-10-28
WO2010138868A3 (en) 2011-04-28
IL216468A0 (en) 2012-01-31
HRP20200298T1 (hr) 2020-06-12
EP3111927B1 (en) 2019-12-11
CN102458364B (zh) 2016-11-02
WO2010138862A3 (en) 2011-04-14
CY1118040T1 (el) 2017-05-17
EP3111927A1 (en) 2017-01-04
LTPA2021511I1 (enExample) 2021-06-25
TWI717511B (zh) 2021-02-01
CA2763936C (en) 2017-10-03
RU2016117972A (ru) 2018-10-29
MX350164B (es) 2017-08-29
TW201808372A (zh) 2018-03-16
LUC00208I2 (enExample) 2022-10-07
TW201109049A (en) 2011-03-16
LT3111926T (lt) 2020-03-25
BRPI1011229B8 (pt) 2021-05-25
NO2019026I1 (no) 2019-06-13
CN105193773B (zh) 2018-12-11
RU2016117972A3 (enExample) 2019-09-27
BRPI1011220B1 (pt) 2020-03-10
JP2012528792A (ja) 2012-11-15
MX350163B (es) 2017-08-29
HUS1900031I1 (hu) 2019-07-29
LUC00124I1 (enExample) 2019-06-13
RU2580315C2 (ru) 2016-04-10
TWI646980B (zh) 2019-01-11
AU2010253776B2 (en) 2015-01-22
NO2021019I1 (no) 2021-05-12
US20170112759A1 (en) 2017-04-27
CN105193773A (zh) 2015-12-30
NL300995I2 (nl) 2019-10-29
US20110023876A1 (en) 2011-02-03
BRPI1011508A2 (pt) 2016-03-22
HK1169026A1 (zh) 2013-01-18
JP2015187108A (ja) 2015-10-29
JP2018008942A (ja) 2018-01-18
PL2435024T3 (pl) 2017-01-31
RU2751771C2 (ru) 2021-07-16
CN102458364A (zh) 2012-05-16
RU2015151358A3 (enExample) 2019-07-29
KR20170070274A (ko) 2017-06-21
PL3111926T3 (pl) 2020-06-29
EP2435024A2 (en) 2012-04-04
DK2435023T3 (en) 2016-10-24
EP2435023B1 (en) 2016-07-06
US20110135737A1 (en) 2011-06-09
KR101926060B1 (ko) 2018-12-06
JP5873012B2 (ja) 2016-03-01
EP2435025B1 (en) 2016-07-06
BRPI1011229B1 (pt) 2020-10-13
US20250009652A1 (en) 2025-01-09
JP2019108369A (ja) 2019-07-04
CY1122807T1 (el) 2021-05-05
CN102596176B (zh) 2017-09-19
PT3111926T (pt) 2020-02-28
RU2580315C3 (ru) 2021-06-18
CN102596176A (zh) 2012-07-18
LT3106149T (lt) 2020-03-10
JP2015199735A (ja) 2015-11-12
WO2010138862A2 (en) 2010-12-02
PT2435025T (pt) 2016-11-11
CN102753152B (zh) 2015-09-23
JP6876734B2 (ja) 2021-05-26
TW201936174A (zh) 2019-09-16
TW201919730A (zh) 2019-06-01
SMT202000108T1 (it) 2020-03-13
ME03631B (me) 2020-07-20
RU2011154148A (ru) 2013-07-10
TWI633898B (zh) 2018-09-01
ES2592536T3 (es) 2016-11-30
SMT202000077T1 (it) 2020-03-13
MX2011012685A (es) 2012-06-12
CN107669664B (zh) 2020-07-10
HUE047834T2 (hu) 2020-05-28
EP3111926B1 (en) 2019-12-11
HUE047823T2 (hu) 2020-05-28
US20170071850A1 (en) 2017-03-16
WO2010138884A2 (en) 2010-12-02
IL216466A0 (en) 2012-01-31
KR20190049943A (ko) 2019-05-09
RU2016107464A3 (enExample) 2019-08-19
JP2017222706A (ja) 2017-12-21
AU2010253770B2 (en) 2014-12-11
KR20120026075A (ko) 2012-03-16
ZA201208101B (en) 2013-07-31
KR101748892B1 (ko) 2017-06-19
HUS2100018I1 (hu) 2021-06-28
KR20170104003A (ko) 2017-09-13
US20210186861A1 (en) 2021-06-24
ZA201208100B (en) 2013-07-31
HUE031283T2 (hu) 2017-07-28
ES2593429T3 (es) 2016-12-09
EP2435024B1 (en) 2016-07-06
HRP20161098T1 (hr) 2016-10-21
CY2019031I2 (el) 2019-11-27
CY1118030T1 (el) 2017-05-17
TW201700123A (zh) 2017-01-01
AU2010253776A1 (en) 2011-11-24
BRPI1011229A2 (pt) 2016-03-15
LTPA2019014I1 (lt) 2019-07-10
PL2435025T3 (pl) 2017-08-31
SMT202000109T1 (it) 2020-03-13
RU2011152960A (ru) 2013-07-10
HK1169027A1 (zh) 2013-01-18
PT3111927T (pt) 2020-03-03
LT3111927T (lt) 2020-03-25
RU2011154083A (ru) 2013-07-10
LUC00124I2 (enExample) 2019-12-27
CN107412212A (zh) 2017-12-01
TW201642836A (zh) 2016-12-16
US20110132357A1 (en) 2011-06-09
IL216466B (en) 2018-08-30
US20180125776A1 (en) 2018-05-10
KR20120015334A (ko) 2012-02-21
JP6169639B2 (ja) 2017-07-26
ES2774391T3 (es) 2020-07-20
KR101976107B1 (ko) 2019-05-09
SI2435023T1 (sl) 2016-10-28
AR076807A1 (es) 2011-07-06
HK1247095A1 (zh) 2018-09-21
MX2020004077A (es) 2020-07-29
IL216468B (en) 2018-12-31
US8808713B2 (en) 2014-08-19
US10716753B2 (en) 2020-07-21
PL3106149T3 (pl) 2020-06-01
US9463161B2 (en) 2016-10-11
CY1118034T1 (el) 2017-05-17
HRP20200166T1 (hr) 2020-05-15
ES2774367T3 (es) 2020-07-20
HUE029532T2 (en) 2017-03-28
LT2435025T (lt) 2016-09-26
HUE031229T2 (en) 2017-06-28
TWI792140B (zh) 2023-02-11
TW201109051A (en) 2011-03-16
MX393243B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
AR076621A1 (es) Composiciones para el suministro de antagonistas muscarinicos de accion prolongada y agonista del receptor adrenergico b2 de accion prolongada. metodo de tratamiento. sistemas asociados. inhalador dosificador
JP2012528200A5 (enExample)
ES2828070T3 (es) Métodos para tratar trastornos autoinmunitarios, respiratorios e inflamatorios mediante la inhalación de n-oxido de roflumilast
ES2666905T3 (es) Composición en solución para aerosol estable presurizada de una combinación de bromuro de glicopirronio y formoterol
ES2464520T3 (es) Formulación en aerosol para EPOC
Singh New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives
US7462645B2 (en) Bronchodilating beta-agonist compositions and methods
ES2666098T3 (es) Combinación de fármacos
RU2019100425A (ru) Новая доза и препаративная форма
RU2013106866A (ru) Фармацевтические композиции
AU2012216890A1 (en) Combination of glycopyrrolate and a beta2 -agonist
JP2018199684A5 (enExample)
RU2013155903A (ru) Композиции, способы и устройства для респираторной доставки двух или более активных средств
JP2012528792A5 (enExample)
JP2013531056A5 (enExample)
ME02342B (me) Farmaceutske formulacije rastvora za izmjerene doze inhalatora pod pritiskom
RU2015154720A (ru) Композиции, способы и системы для респираторной доставки трех или более активных средств
ES2961242T3 (es) Terapia combinada para la EPOC
HRP20192010T1 (hr) Muskarinski antagonisti i njihove kombinacije za liječenje bolesti dišnih puteva kod konja
KR20120022751A (ko) 스테로이드성［３,２?ｃ］피라졸 유도체 및 제２ 제약 활성 화합물을 포함하는 제약 조성물
RU2012125043A (ru) Ингаляционные растворы
ES2610104T3 (es) Aclidinio para el uso en la mejora de la calidad del sueño en pacientes con enfermedades respiratorias
ES2467928T3 (es) Formulación en aerosol para EPOC
TW201023916A (en) Methods of using a thiazole derivative
ES2917879T3 (es) Nuevo uso de aclidinio

Legal Events

Date Code Title Description
FC Refusal